cardiovascular benefits of glp-1 agonists glucagon-like peptide-1 receptor GLP-1 Receptor Agonists: The Game-Changer

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection

Physician-supervised GLP-1 weight loss with Tirzepatide, offering personalized care in Glendale, La Caada and Burbank

The FDA has also warned about risks during surgery because the drug slows digestion

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D